A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of house dust mites of Dermatophagoides pteronyssinus in patients with rhinitis/rhinoconjunctivitis with or without allergic asthma bronchiale [Estudio multicentrico, aleatorizado, controlado con placebo y doble ciego para evaluar la seguridad y la eficacia de una inmunoterapia especifica con una preparacion alergoide de acaros del polvo Dermatophagoides pteronyssinus adsorbida en hidroxido de aluminio en pacientes con rinitis/rinoconjuntivitis con o sin asma bronquial alergica]

Trial Profile

A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of house dust mites of Dermatophagoides pteronyssinus in patients with rhinitis/rhinoconjunctivitis with or without allergic asthma bronchiale [Estudio multicentrico, aleatorizado, controlado con placebo y doble ciego para evaluar la seguridad y la eficacia de una inmunoterapia especifica con una preparacion alergoide de acaros del polvo Dermatophagoides pteronyssinus adsorbida en hidroxido de aluminio en pacientes con rinitis/rinoconjuntivitis con o sin asma bronquial alergica]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2013

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Allergic rhinitis; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top